Table 1.
Synopsis of MSCs and TAFs similarities and differences
| MSCs | TAFs | |
|---|---|---|
| Pluripotency (trilineage differentiation potential) | Yes | Yes |
| Cell surface molecules | ||
| CD14 | − | – |
| CD29 | + | + |
| CD31 | − | – |
| CD34 | − | – |
| CD44 | + | + |
| CD45 | − | – |
| CD73 | + | + |
| CD90 | + | + |
| CD106 | + | + |
| CD117 | + | + |
| HLA-DR | − | – |
| CXCR4 | − | – |
| VEGF-R1 (Flt-1) | − | – |
| VEGF-R2 (Kdr) | − | – |
| TGF-β RII | − | – |
| TGF-β RII | − | – |
| Cytoskeleton and extracellular matrix proteins | ||
| Vimentin | Yes | Yes |
| α-SMA | Yes | Yes |
| Nestin | Yes | Yes |
| Cytokeratin | No | No |
| E-cadherin | No | No |
| Ultrastructural details | ||
| Cytoplasmic elongations | No | Yes |
| Lamellar content lysosomes | No | Yes |
| Intermediate filaments | Yes | No |
| Cytokines, chemokines and growth factors secretion | ||
| IL-4 | Low | High |
| IL-10 | Low | High |
| IL-13 | Low | High |
| TGF-β1 | Low | High |
| TNF-α | Low | High |
| VEGF | Low | High |
+: expression; −: lack of expression.